

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Remidio receives regulatory approval from Karnataka to deploy AI-based tools for eye care

02 May 2025 | News

For early detection of glaucoma and age-related macular degeneration (AMD) in diverse healthcare settings



Remidio Innovative Solutions has received approval from the State FDA, Karnataka (CDSCO), the regulatory authority for medical devices, for its Medios HI (Humanising Intelligence) Glaucoma AI and Medios HI AMD AI.

This approval represents an important advancement in the use of artificial intelligence (AI) for early detection of glaucoma and age-related macular degeneration (AMD) in diverse healthcare settings.

Following the success of the CDSCO-approved Medios DR HI, AI for diabetic retinopathy, which has impacted nearly 2,50,000 patients in the past year, the newly approved AI solutions for glaucoma and AMD are also designed to function offline. This offline capability allows real-time analysis without relying on internet access, making it useful for providing eye care in remote and underserved areas with limited access to specialised ophthalmic diagnostics.

Medios HI Glaucoma AI exceeds conventional screening methods by analysing optic nerve head and RNFL structures, generating heat map-based reports to detect early signs of referable glaucoma. This is vital in a country like India, which accounts for 12 million glaucoma patients, nearly one in eight globally. Yet over 90% of these cases remain undiagnosed, often leading to irreversible vision loss. Early detection using portable, AI-enabled tools can drastically change this trajectory.

The Medios HI AMD AI, detects early-stage age-related macular degeneration (AMD), a major cause of vision impairment among the elderly. With 2.1% of Indians over age 60 affected, amounting to nearly 6.7 million people at risk, this tool plays a crucial role in enabling timely referrals and preventive care by highlighting lesions with AI generated heat maps.

Medios HI Glaucoma and Medios HI AMD AI has been clinically validated across tertiary hospitals, eye institute and vision centres showcasing high level of sensitivity and specificity. With Medios HI on Remidio's FOP NM 10, a single tap delivers results for screening AMD, Glaucoma, and DR in few seconds. Three critical insights, one seamless experience.

Dr R. Kim, Chief Medical Officer, Senior Medical Consultant, Retina & Vitreous Services Director, Aravind Eye Hospital, Madurai said "The Remidio fundus camera isn't just an imaging device; it's a portable gateway to early detection and prevention of vision-threatening conditions, bringing quality eye care closer to those who need it most"

Dr Anand Sivaraman, CEO and Founding Director, Remidio said "The CDSCO's approval of our Medios HI Glaucoma AI and Medios HI AMD AI builds upon the foundation laid by our Medios HI DR AI, which was the first ophthalmic AI software to receive such approval in India."